Results 141 to 150 of about 25,818 (186)

Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial. [PDF]

JTO Clin Res Rep
Landi L, Chiari R, Tiseo M, Metro G, de Marinis F, Delmonte A, Novello S, Cortinovis DL, Galetta D, Bonanno L, Gridelli C, Morabito A, Grossi F, Torchia A, Giannarelli D, Borra G, Mazzoni F, Pilotto S, Cappuzzo F.   +18 more
europepmc   +1 more source

Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. [PDF]

Mol Cancer Ther
Matkar S, East MP, Stuhlmiller TJ, Witek GM, Farrel A, Pastor S, Okumu DO, Kennedy A, Kalna JR, Berko ER, Casey CE, Krytska K, Patel K, Rokita JL, Gerelus M, Maris JM, Johnson GL, Mossé YP.   +17 more
europepmc   +1 more source

Unraveling the impact of crizotinib to promote megakaryopoiesis for alleviating thrombocytopenia in myelodysplastic neoplasms. [PDF]

Leukemia
Kobayashi H, Komizo Y, Watanabe N, Miyata Y, Ohnuma Y, Kamimura-Aoyagi Y, Yuki K, Hayashi Y, Yoshida M, Harada Y, Harada H.   +10 more
europepmc   +1 more source

Neoadjuvant Alectinib in a Patient With Anaplastic Lymphoma Kinase (ALK)-Mutant Stage III Lung Adenocarcinoma: A Case Report. [PDF]

Cureus
Dastagir ML, Bajaman J, Reynolds JA.
europepmc   +1 more source

Advances and updates in pediatric anaplastic large cell lymphoma. [PDF]

Blood Adv
Marks LJ, Lowe E, Kamdar K.
europepmc   +1 more source

ALK-Targeted Therapy: Resistance Mechanisms and Emerging Precision Strategies. [PDF]

Curr Issues Mol Biol
Zhang YK, Tong JB, Luo MX, Qin ZP, Wang R.   +4 more
europepmc   +1 more source

Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer. [PDF]

Transl Lung Cancer Res
Morise M, Tanaka I, Ishii M.
europepmc   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients. [PDF]

Mol Oncol
Zwierenga F, Dijkhuizen C, Korthuis P, Timens W, Groen H, Hiltermann J, van den Berg A, Drayer L, van der Wekken A.   +8 more
europepmc   +1 more source

Long-Term Safety and Management of Adverse Events Associated With Lorlatinib in <i>ALK</i>-Positive Metastatic NSCLC: A Fictional Case Study. [PDF]

J Adv Pract Oncol
Krueger EA, Castronovo E, Cho E, Alejandro L, Mcdonald S, Oshiro CB, Lewis W.   +6 more
europepmc   +1 more source

Taletrectinib in ROS1-positive NSCLC: bridging clinical trials and real-world practice. [PDF]

Ann Med Surg (Lond)
Zahra FT, Naveed F, Fatima M.
europepmc   +1 more source